Business
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population[1].
About this update from Volitionrx Limited
[{"type":"text","content":"Nu.Q® Biomarker Paper Available on MedRXIV ","length":42,"tagName":"p"},{"type":"text","content":"HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for a chronic disease, Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population[1].","length":406,"tagName":"p"},{"type":"text","content":"The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway) and the U.K.","length":291,"tagName":"p"},{"type":"text","content":"Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added:","length":87,"tagName":"p"},{"type":"text","content":""We are excited to report the findings of this clinical study, which focused on a chronic disease, HS. It paves the way to improve a patient's management through a personalized medicine approach.","length":204,"tagName":"p"},{"type":"text","content":""This study, together with previously published evidence[2-5], demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions.","length":261,"tagName":"p"},{"type":"text","content":""Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opportunity for such indications is significant, with a Total Addressable Market of $3.8 billion[6]."","length":222,"tagName":"p"},{"type":"text","content":"Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece, and co-author of the paper said:","length":192,"tagName":"p"},{"type":"text","content":""Hidradenitis suppurativa is a complex immune-mediated disorder, with multiple proinflammatory cytokines contributing to its pathogenesis. The clinical presentation may also vary from person to person, making it c...